Top EKSO BIONICS Insiders Make Bold Moves With Fresh Share Purchases

New insider activity at EKSO BIONICS ( (EKSO) ) has taken place on March 20, 2026.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential EKSO BIONICS has seen notable insider activity as two top executives increased their stakes in the company. Chief Operating Officer Jason C Jones acquired 1,308 shares of EKSO BIONICS stock in a transaction valued at $15,499. In a parallel move, Chief Financial Officer Jerome Wong also purchased 1,308 shares, likewise totaling $15,499. These coordinated insider purchases by both the COO and CFO signal strengthened executive confidence in the company’s future prospects. Recent Updates on EKSO stock Ekso Bionics’ recent disclosure focuses on heightened trade-secret and patent risks in its IP-intensive medical device business, where infringement and misappropriation claims are frequent and costly, potentially distracting management and constraining product sales. Dependence on co-owned patents with UC Berkeley, some non-exclusive or licensed to third parties, raises uncertainty over long-term control of key technologies and could increase litigation and royalty burdens. Adverse infringement outcomes could impose substantial damages, restrictive licensing terms, or injunctions that limit current product lines and future innovations, while efforts to enforce its own patents may trigger counterclaims, narrow or invalidate protections, and expose confidential information, undermining IP value. These evolving legal and IP risks are central to how analysts reassess the company’s outlook and inform recent stance shifts without necessarily reflecting major price moves in the last day. Spark’s Take on EKSO Stock According to Spark, TipRanks’ AI Analyst, EKSO is a Neutral. The score is held back mainly by weak financial performance (ongoing losses and cash burn with recent revenue decline) and a negative earnings-based valuation signal. These are partially offset by strong technical uptrend indicators and mixed corporate-event catalysts, including a major strategic pivot but with substantial dilution and control-transfer risk. To see Spark’s full report on EKSO stock, click here. More about EKSO BIONICS YTD Price Performance: 20.37% Average Trading Volume: 2,160,466 Technical Sentiment Signal: Buy Current Market Cap: $37.06M